Stress Shortened Astrocyte Cilia in Mice
A Nature study links stress to shorter signalling cilia on amygdala astrocytes and shows pathway-based behavioural improvement in mice, not a treatment for human anxiety.
The 60-second version
Stress shortened primary cilia on amygdala astrocytes, and restoring related signalling improved some behavioural measures in mice.
Key points
- Three mouse stress models linked astrocyte molecular changes to shorter primary cilia in the amygdala.
- Engineered Gi signalling and native S1PR1 targeting restored cilium length and selected behavioural outcomes.
- Ponesimod did not normalize all stress physiology or all behavioural measures.
- Human data showed expression and disease-associated gene patterns, not treatment efficacy.
Verdict. A detailed mouse mechanism and a plausible research target, but no evidence yet for treating human anxiety by targeting astrocyte cilia or repurposing ponesimod.
Bottom lineWhat the study established
In several mouse stress models, astrocytes in the amygdala showed altered cilia-related genes and proteins, while their primary cilia became shorter. Activating astrocyte signalling restored cilium length and accompanied improvement on some behavioural tests.
Primary cilia are small membrane projections that organize cellular signals. The change was specific enough to be informative: cilia shortened on amygdala astrocytes, but not on nearby neurons or cortical astrocytes in the reported comparisons.
DesignHow the mouse evidence was built
| Stress models | Fourteen days of chronic restraint or water avoidance, plus a separate spared-nerve-injury model of pain-related stress. |
|---|---|
| Main stress cohorts | About 18–20 unstressed mice and 10 mice in each restraint or water-avoidance group for key physiological measures; individual experiments used different cohorts. |
| Cell measurements | Astrocyte-selective RNA sequencing, near-membrane proteomics and microscopy of cilium markers. |
| Causal tests | Engineered Gi signalling, native S1PR1 targeting and selective genetic disruption of astrocyte cilia. |
| Human component | Postmortem tissue and reanalysis of existing single-nucleus gene-expression datasets, not a clinical intervention. |
After chronic restraint or water avoidance, roughly 80% of amygdala astrocytes still carried detectable cilia, but the cilia were shorter and smaller. Stress also shifted dozens of astrocyte genes, with cilia-related pathways prominent among the downregulated signals.
InterventionWhat improved and what did not
Astrocyte-specific activation of an engineered Gi receptor restored cilium length and improved selected stress-related readouts. The team then used ponesimod to activate native S1PR1 signalling. In groups of 10 mice, sucrose-preference and forced-swim outcomes moved toward unstressed controls; imaging in 4 mice per group showed restored cilium length.
Better scores on selected mouse tests are not the same as treating human anxiety.
Human evidenceExpression is not clinical efficacy
Cilia-related genes were widely expressed in human amygdala astrocytes. S1PR1 was detected in about half of ALDH1L1-positive astrocytes across four neurotypical donors, and psychiatric datasets contained altered cilia-related gene patterns. These observations connect the mechanism to human biology, but they do not show cilium shortening after human stress or symptom improvement after pathway targeting.
LimitsReasons for caution
- Mouse open-field, sucrose-preference and forced-swim tests are behavioural proxies, not diagnoses of anxiety or depression.
- Some imaging and molecular comparisons used four mice per group, even when many cells were measured.
- Mice were randomized, but the authors report that blinding was not always feasible; automated scoring reduced some subjectivity.
- The paper does not define a clinically meaningful cilium-length threshold.
- Human analyses were postmortem and observational, so they cannot establish treatment causality.
Practical meaningWhat to do now
Do not start, stop or repurpose ponesimod on the basis of this study. The next useful evidence is independent replication, direct measurement in human-relevant systems and clinical research that separates biomarker change from meaningful symptom benefit and safety.